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Objective: Dystonia is occasionally found in patients with Parkinson's disease (PD) and atypical
parkinsonisms. However, systematic comparative analysis of the association between dysto-
nia and parkinsonism have seldom been reported. The goals of this study are to compare the
clinical characteristics and distributions of dystonia between PD, multiple system atrophy
(MSA), progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD).
Methods: We prospectively enrolled 176 patients who presented with dystonia and parkin-
sonism out of 1278 patients with parkinsonism. We analyzed the clinical features of
dystonia and parkinsonism.
Results: The frequencies of dystonia were 11.0% in PD, 20.9% in MSA, 40.7% in PSP and 66.7% in
CBD. Dystonia symptoms were most frequent in CBD and relatively more frequent in PSP and
MSA ( p < 0.001). Moreover, multiple types of dystonia occurred most frequently in MSA
( p = 0.034). According to the distribution of dystonia, cranio-facial dystonia (CFD) and cervical
dystonia (CD) were more frequently observed in atypical parkinsonism ( p = 0.001). In contrast,
limb dystonia (LD) was more frequently observed in both PD and CBD, and truncal dystonia
(TD) was more frequently detected in PD ( p < 0.001). Levodopa medication related dystonia
was markedly more frequent in PD than in atypical parkinsonism ( p = 0.030).
Conclusions: In this long-term, observational, prospective study, we concluded that levodopa
medication related LD and TD were more frequently observed in PD than in atypical
parkinsonism. Conversely, levodopa medication non-related CFD and CD were more fre-
quently observed in atypical parkinsonism, and coexisting of some types of multiple
dystonia may be unique features of atypical parkinsonism. TD or multiple types of LD,
might be representative of PD rather than atypical parkinsonism.
© 2017 Published by Elsevier Sp. z o.o. on behalf of Polish Neurological Society.
* Correspondence to: Department of Neurology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, #29 Saemu-
nan-ro, Jongno-gu, Seoul 03181, Republic of Korea.
E-mail addresses: wtyoon@skku.edu, wtyoon@gmail.com
Available online at www.sciencedirect.com
ScienceDirect
journal homepage: http://www.elsevier.com/locate/pjnnshttps://doi.org/10.1016/j.pjnns.2017.11.004
0028-3843/© 2017 Published by Elsevier Sp. z o.o. on behalf of Polish Neurological Society.
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 4 8 – 5 3 491. Introduction
Dystonia is a syndrome that is characterized by sustained
muscle contraction associated with twisting, repetitive, and
patterned movements, abnormal posture, or both [1]. Dystonia
may coexist with parkinsonism in a number of neurodegen-
erative, genetic, toxic, and metabolic disorders of which
Parkinson's disease (PD) and atypical parkinsonisms are the
most common [2,3]. Clinical associations between and dysto-
nia and various parkinsonisms have been reported in some
studies [4–7]. Although rare, one such study also reported the
overall frequency and clinical features of dystonia in atypical
parkinsonism [8].
However, the clinical relationships remain unclear; for
example, one study commented that the true frequency and
range of dystonia manifestations remain unknown in autop-
sy-proven cases of parkinsonism, including multiple system
atrophy (MSA), progressive supranuclear palsy (PSP), corti-
cobasal degeneration (CBD) and PD [9], and systematic
prospective, comparative analysis of the clinical features of
dystonia associated with parkinsonism have seldom been
reported.
The aims of the present study were to investigate the
clinical characteristics of dystonia associated with parkinson-
ism in a larger patient sample than that in previous reports
and compare these characteristics among the various types of
parkinsonism to identify the clinical usefulness of the
distributive pattern of dystonia in the differential diagnosis
of parkinsonism.
2. Materials and methods
Between January 2002 to December 2004, we investigated 185
consecutive patients who presented with dystonia combined
with parkinsonism. Among these patients, we prospectively
enrolled 176 patients who presented with dystonia combined
with parkinsonism out of 1278 patients with parkinsonism
registered at the Movement Disorder Clinic of the Samsung
Medical Center during the same period, from January 2002 to
December 2004. We included patients with long-term follow-
up data over ﬁve years (to December 2009), full evaluations for
parkinsonism and clinical diagnoses conﬁrmed by at least two
specialist neurologists from movement disorder clinics. Under
the established diagnostic criteria [10–15], 1278 patients with
parkinsonism were divided into 1045 patients with PD, 191
patients with MSA, 27 patients with PSP and 15 patients with
CBD. Moreover, we excluded 9 patients with uncertain
diagnosis of parkinsonism (n = 2), those lost to follow-up
(n = 2) and those with combined dystonia due to medical or
neurological reasons other than parkinsonism with the
following other diagnosis: dementia with Lewy bodies (DLB)
(n = 2), normal pressure hydrocephalus (NPH) (n = 1), metabolic
encephalopathy (n = 1), and post-stroke parkinsonism with
dystonia (n = 1).
We clinically diagnosed dystonia using the established
deﬁnition [2,16] and analyzed the clinical features of dystonia
and parkinsonism, including demographics, the temporal
proﬁles of the symptoms, the distribution and characteristicsof dystonia, the clinical diagnosis of parkinsonism and the
relationship with levodopa treatment. Dystonia was subclas-
siﬁed as cranio-facial dystonia (CFD), cervical dystonia (CD),
truncal dystonia (TD) and limb dystonia (LD) according to the
distribution of dystonia among the enrolled parkinsonism
patients, and we also clinically examined cases of unusual
dystonia phenotypes, such as dystonia preceding parkinson-
ism (Pre-Dystonia) and clinically dominant dystonia if there
were multiple coincidently emerging variant types of dystonia
(Multi-Dystonia), as occurred in one parkinsonism patient.
All data are presented as the mean  standard error of the
mean (SEM). The PASW (Version 22.0; IBM SPSS Inc., Chicago,
IL) program for Windows was used for statistical analysis. The
baseline demographic and clinical data were analyzed by
Student's t-test, and data regarding sex differences and the
number of subjects with the presence of dystonia between
each group were analyzed using the chi-square test. Data
related to age of onset, the interval from onset to parkinson-
ism, and the number of characteristics regarding dystonic
symptoms were analyzed using one-way analysis of variance
(one-way ANOVA). Fisher's exact test was used to evaluate the
difference in the number of dystonias between each group,
and the statistical signiﬁcance level was set at p < 0.05.
3. Results
Among 176 dystonic patients with parkinsonism, 115 patients
were clinically diagnosed with PD, 40 were probable MSA, 11
were probable PSP, and 10 were probable CBD. Fig. 1 shows the
patient ﬂow, including information about 9 excluded patients.
Demographic and clinical proﬁles of the dystonic patients in
each parkinsonism group are presented in Table 1. Among the
total 1278 parkinsonism patients (1045 PD, 191 MSA, 27 PSP and
15 CBD), the frequencies of dystonia among each parkinson-
ism type were 11.0% (115/1045) in PD, 20.9% (40/191) in MSA,
40.7% (11/27) in PSP and 66.7% (10/15) in CBD. Overall, dystonia
symptoms were more frequent in CBD and PSP than in PD
( p < 0.001), and in terms of sex differences, dystonia was more
frequent in men than in women among PSP patients
( p = 0.019). The onset age of initial dystonic symptoms was
older in CBD and younger in PD ( p < 0.001).
In CBD patients, only limb dystonic symptoms without
other types of dystonia were observed, with no unusual Pre-
Dystonia phenotypes. Despite the small number of patients,
Multi-Dystonia was relatively more frequent in MSA than in PD
or PSP ( p = 0.034). Aside from these ﬁndings, no other
signiﬁcant clinical demographic differences were observed
among the various types of parkinsonism (Table 1).
According to the distribution of dystonia, CFD and CD were
more frequently observed in atypical parkinsonism (39/61,
63.9% and 7/61, 11.5%, respectively) than in PD (16/115, 13.9%
and 1/115, 0.9%, respectively) ( p < 0.001). In contrast, TD and
LD were more frequently observed in PD (32/115, 27.8% and 66/
115, 57.4%, respectively) than in atypical parkinsonism (2/61,
3.3% and 13/61, 21.3%, respectively) ( p = 0.001). TD, including
camptocormia, was detected only in PD and levodopa
medication non-related MSA ( p < 0.001). In terms of the
relationship with levodopa treatment, levodopa medication
related dystonia was markedly more frequent in PD than in
Table 1 – Demographic and clinical profiles of dystonic patients in each type of parkinsonism.
Patients PDa MSAb PSPc CBDd p Value
Dystonia/total patients (N) 115/1045 40/191 11/27 10/15 <0.001
(Prevalence of dystonia, %) (11.0%) (20.9%) (40.7%) (66.7%)
Sex (M/F) 41/74 19/21 9/2 5/5 0.019
Onset age (y): initial symptom 54.6  10.8 60.8  9.0 59.8  4.1 67.1  7.7 <0.001
Onset interval (m): to dystonia 54.9  45.6 41.9  35.6 47.5  43.5 69.0  28.7 0.217
Multiple types of dystonia (N) 12 18 5 0 0.034
Preceding dystonia to parkinsonism (N) 8 5 2 0 NAe
a Parkinson's disease (PD).
b Multiple system atrophy (MSA).
c Progressive supranuclear palsy (PSP).
d Corticobasal degeneration (CBD).
e Not available (NA).
Fig. 1 – Patient flow. DLB, dementia with Lewy bodies; NPH, normal pressure hydrocephalus; PD, Parkinson's disease; MSA,
multiple system atrophy; PSP, progressive supranuclear palsy; CBD, corticobasal degeneration.
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frequent in PD regardless of the relationship with levodopa
medication, CFD and CD were more frequent in levodopa
medication non-related atypical parkinsonism ( p < 0.001), and
LD was more frequent in levodopa medication related PD, as
shown in Table 2 ( p = 0.030).
Among the 35 patients with multiple types of dystonia,
twenty-three were diagnosed with atypical parkinsonism, and
twelve were diagnosed with PD. According to the subclasses of
the combinations of multiple types of dystonia, combinationgroups with two-variable CFD or CFD with CD were observed
only in atypical parkinsonism, and other combination groups
of CD with LD, TD with LD and two-variable LD were observed
only in PD (Table 3). Excluding some small groups of patients,
the two major multiple-type dystonias were two-variable CFD
(19/35, 54.3%) and two-variable LD (7/35, 20%), with all patients
in the former group being diagnosed as atypical parkinsonism
(15 MSA and 4 PSP) and all patients in the latter group being
diagnosed as PD with signiﬁcant clinical and demographic
differences ( p < 0.001).
Table 2 – Distribution of dominant dystonia in each parkinsonism patient according to the relationship with levodopa
medication.
Parkinsonism PDa Atypical
parkinsonism (AP)
MSAb PSPc CBDd p-Value
PD vs. AP/All groups
Total number of dystonic patients (N) 115 61 40 11 10 <0.001/0.001
CFDe (N) 16 39 31 8 0
CDf (N) 1 7 5 2 0
TDg (N) 32 2 2 0 0
LDh (N) 66 13 2 1 10
Levodopa medication non-related 58 55 35 11 9 <0.001/<0.001
CFDe (N) 6 36 28 8 0
CDf (N) 0 6 4 2 0
TDg (N) 24 2 2 0 0
LDh (N) 28 11 1 1 9
Levodopa medication related 57 6 5 0 1 0.034/0.030
CFDe (N) 10 3 3 0 0
CDf (N)f 1 1 1 0 0
TDg (N) 8 0 0 0 0
LDh (N) 38 2 1 0 1
a Parkinson's disease (PD).
b Multiple system atrophy (MSA).
c Progressive supranuclear palsy (PSP).
d Corticobasal degeneration (CBD).
e Cranio-facial dystonia (CFD).
f Cervical dystonia (CD).
g Truncal dystonia (TD).
h Limb dystonia (CBD).
Table 3 – Distribution of multiple types of dystonia in each type of parkinsonism.
Parkinsonism PDa Atypical
parkinsonism (AP)
MSAb PSPc CBDd p-Value
PD vs. AP/All groups
Total number of patients with
multiple dystonias (N)
12 23 18 5 0 <0.001/<0.001
Multiple types of dystonia
CFDe + CFDe (N) 0 19 15 4 0
CFDe + CDf (N) 0 2 1 1 0
CFDe + TDg (N) 1 1 1 0 0
CFDe + LDh (N) 1 1 1 0 0
CDf + TDg (N) 0 0 0 0 0
CDf + LDh (N) 1 0 0 0 0
TDg + LDh (N) 2 0 0 0 0
LDh + LDh (N) 7 0 0 0 0
a Parkinson's disease (PD).
b Multiple system atrophy (MSA).
c Progressive supranuclear palsy (PSP).
d Corticobasal degeneration (CBD).
e Cranio-facial dystonia (CFD).
f Cervical dystonia (CD).
g Truncal dystonia (TD).
h Limb dystonia (CBD).
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In this long-term, observational study, we prospectively
surveyed dystonia in patients with parkinsonism. In cases
with coexisting dystonia and parkinsonism, we retrospective-
ly analyzed the distribution and characteristics of dystoniaand prospectively investigated the clinical pattern of dystonia,
the relationship between dystonia and levodopa treatment,
and the long-term prognosis to conﬁrm the clinical diagnosis.
Parkinsonism and dystonia may coexist not only in
neurodegenerative disorders such as PD, MSA, PSP and CBD
but also in a number of genetic, toxic and metabolic disorders
and as a result of structural lesions in the basal ganglia [2].
Some reports have described the characteristics of the
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parkinsonism or PD [4,6–8,17,18]. In most of these previous
studies, the overall frequency of dystonia was found to be
relatively high in atypical parkinsonism. However, few studies
have compared PD and each atypical parkinsonism. Further-
more, no descriptions regarding the presence of multiple other
types of dystonia and preceding dystonia parkinsonism are
available, except in some cases reports [19,20].
In terms of the symptoms of each dystonic, previous
clinical studies have reported the clinical subtypes of dystonia
in parkinsonism. For example, blepharospasm, a type of CFD,
is common and more prevalent in atypical parkinsonism than
in PD [21,22]. Although these studies are rare, one recent study
reported the clinical subtypes of anterocollis in parkinsonian
syndromes, ﬁnding no other signiﬁcant clinical differences
between the clinical subtypes of anterocollis or primary
diagnosis, with the exception that patients with atypical
parkinsonian syndromes had more advanced motor symp-
toms [23]. Another study reported on reversible Pisa syndrome
in PD patients on dopaminergic therapy. Similar to the results
of our study, a clinically important association between Pisa
syndrome as a TD in patients with PD and dopaminergic
therapy was found [24].
In general, PD is associated with the loss of midbrain
dopamine neurons [25], and parkinsonism and dystonia have
been reported to occur subsequent to strokes in various sites in
the basal ganglia, including the striatum and globus pallidus
[26–29]. However, some other studies have revealed that
dystonia and parkinsonism might be associated with other
focal brain lesions or brainstem lesions [30,31]. For these
reasons, the co-existence of dystonia and parkinsonism
usually results from multiple lesions or the involvement of
more than one pathway [2], and one recent animal study
reported that parkinsonism and dystonia are differentially
induced by the modulation of different territories of the basal
ganglia [32]. The pathophysiology and mechanism underlying
the co-existence of parkinsonism and dystonia remain
unknown, but clinical presentations of dystonia in PD and
atypical parkinsonism are relatively common, and dystonia
among the clinical set of symptoms and signs associated with
parkinsonism may have diagnostic value in the differential
diagnosis of parkinsonism [2,22].
In terms of the relationship between dystonia and levodopa
treatment, we also found that dystonia may have occurred as
an 'off' symptom or as a 'peak-dose' effect of levodopa
treatment. Dystonia that is improved by levodopa treatment is
more strongly related to PD, while some dystonic symptoms
that are aggravated by levodopa treatment are more strongly
related to atypical parkinsonism. Moreover, in terms of the
relationship between dystonia preceding and following par-
kinsonism, we also found that some preceding dystonia may
occur as a prodromal symptom of parkinsonism, and preced-
ing dystonia is more strongly related to atypical parkinsonism.
However, these two suggestions were not statistically con-
ﬁrmed because the number of patients was small. Additional-
ly, we could not assess the history of other medications,
mainly including dopamine agonists and anticholinergics,
which would have potential effects on dystonia in parkinson-
ism patients. This point is more likely to be encountered in the
clinic, and this issue will be a good subject for clinical studies ofdifferential diagnoses in parkinsonism if prospective observa-
tions are performed in the future.
According to our experience during the progression of this
study, most cases of CFD and CD were treated with botulinum
toxin injection, and most cases of TD and LD were treated with
symptomatic medications, including muscle relaxants or
anticholinergics and changes in levodopa medication dose.
Even though these treatment results regarding dystonic
symptoms in all groups were not statistically evaluated
because of too many variable factors, many CFD patients
treated with botulinum toxin injection might have a good
prognosis. Additionally, compared with CD and TD patients,
many LD patients treated with medications might have a
relatively good prognosis regardless of the methods of
treatment.
This study had several limitations. First, even though
patient enrollment was conducted in a prospective study
design, after enrollment, the clinical data of some patients
regarding dystonia and parkinsonism were retrospectively
corrected using the patients' direct explanations and subjec-
tive history taking. However, the clinical features of the
presence of a single type or multiple types of dystonia and the
comparative prevalence of dystonia among all study subjects
were systemically evaluated. Second, we conducted this study
based on only clinical diagnosis of parkinsonism. Clinico-
pathologic evaluations of the correlation between dystonia
and parkinsonism and conﬁrmation of neuropathological
diagnosis would be needed to disclose the relationship
between dystonic manifestations and pathological substrates
of each type of parkinsonism. Third, the pattern and
distribution of dystonia and dystonia's co-existence with
parkinsonism were assessed for this study. The severity and
frequency of dystonia measured by a clinical scale regarding
dystonia and the frequency and average of levodopa medica-
tion dose were not assessed in detail, which should be
considered in future comprehensive studies. Fourth, in
addition to levodopa medications, other medications, includ-
ing dopamine agonists, antipsychotic medications, antide-
pressants, and symptomatic medications for the treatment of
dystonia, were not assessed in detail. However, in this study,
relationships between levodopa medication and dystonia
were critically observed in all study subjects during the
long-term follow-up period regardless of other medications.
Fifth, we could not evaluate the previous history of other
neurological disorders and medical problems, which could
possibly affect the dystonic symptoms or could be hidden
causative factors. Future studies with well-designed, detailed
evaluations of all factors and long-term comparison between
dystonia and parkinsonism are needed to solve these
fundamental issues.
5. Conclusions
In summary, this study demonstrated that the symptoms of
dystonia were most frequent in CBD and more frequent in
atypical parkinsonism (e.g., CBD, PSP and MSA, in descending
order of frequency) than in PD. Moreover, levodopa medication
non-related CFD including blepharospasm or CD, were more
frequently observed in atypical parkinsonism (MSA and PSP),
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types of CFD or CFD with CD) may be a unique feature of
atypical parkinsonism. Conversely, all TD and LD groups were
more frequently observed in PD than in atypical parkinsonism,
regardless of levodopa medication. TD, including camptocor-
mia or multiple types of LD, might therefore be representative
of PD rather than atypical parkinsonism. Moreover, levodopa
medication related LD and TD presenting as 'off' symptoms,
'peak-dose' effects or levodopa responsiveness might be
representative of PD and not atypical parkinsonism.
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